Rilmakalim hemihydrate

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRilmakalim hemihydrate
Drug Alias NameRimalkalim利马卡林RilmakalimumHOE-234
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSulfonylurea receptor agonists
TargetsSulfonylurea receptor
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofi
Active IndicationsN/A
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A